Phase 1Not yet recruiting
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of GV-100 (Part3)
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of GV-100 with Food-Effect and Drug-Drug Interaction Evaluations in Healthy Participants ((Part 3)
- Sponsor
- Gilva Therapeutics, INC.
- Enrolment
- 12 planned
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD); Renal and Urogenital - Kidney disease
- Ages
- adults, older adults
- Registry
- ACTRN12626001130358
Full record on ANZCTRSource: WHO ICTRP, processed 14 September 2026
Primary outcomes
- Part 3: Safety and tolerability will be assessed as a composite outcome, including adverse events (AEs), vital signs, 12-lead ECGs, and safety laboratory tests for Fed and Fasting condition[Safety and tolerability will be assessed compositely. Adverse Events: AEs will be coded using the latest versi
History
Expected to start
Last registry update
Registered